Revistas
Revista:
INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
ISSN:
1672-5123
Año:
2013
Vol.:
6
N°:
6
Págs.:
801-804
Two controlled, prospective, randomized, single-blind studies were performed. In the first study, a total of 80 eyes from 40 outpatient-clinic patients were analyzed. PT drops were applied to the right eye, and a MY device was inserted in the left eye for 30min. Time until maximal pupil dilation for each eye was then assessed. In the second study, 80 eyes from 80 patients undergoing cataract surgery were analyzed. Pupil dilation was achieved using either PT drops three-times for one hour prior to surgery (40 patients), or a MY device was inserted one hour prior to surgery (40 patients).
In the first study, MY achieved superior mydriasis compared to PT eye drops at 90min (9.04±1.33mm vs 8.78±1.37mm, P=0.012). However MY took longer than PT drops to achieve maximal dilation, and mydriasis was inferior in eyes with MY compared to PT drops at 30min (7.21±1.73mm vs 8.22±1.43mm, P<0.001), the two groups only becoming similar by 60min (8.85±1.44mm vs 8.71±1.27mm, P=0.236). In the second study, both MY and PT achieved similar levels of mydriasis at the beginning of surgery (8.75±0.76mm with MY vs 8.77±0.63mm with PT), and also at the end of surgery (7.96±1.06mm with MY vs 8.32±0.72mm with PT), with no significant difference between groups (P=0.08). MY was well tolerated and cardiovascular effects were not influenced by dilation method.
Revista:
JOURNAL OF CATARACT AND REFRACTIVE SURGERY
ISSN:
0886-3350
Año:
2011
Vol.:
37
N°:
3
Págs.:
612 - 613
Autores:
Recalde, Sergio; Zarranz Ventura, J.; Fernández Robredo, P.; et al.
Revista:
INVESTIGATIVE OPHTHALMOLOGY AND VISUAL SCIENCE
ISSN:
0146-0404
Año:
2011
Vol.:
52
N°:
10
Págs.:
7090 - 7097
TGF-ß inhibition with these peptides represents a promising new therapeutic line for CNV targeting a different pathway than current therapies. More studies are needed to assess this effect on early CNV, alone or in combination with anti-VEGF.
Revista:
European journal of ophthalmology
ISSN:
1120-6721
Año:
2010
Vol.:
21
N°:
4
Págs.:
439 - 449
Revista:
EUROPEAN JOURNAL OF OPHTHALMOLOGY
ISSN:
1120-6721
Año:
2010
Vol.:
20
N°:
2
Págs.:
442 - 450
Purpose. To estimate the prevalence and causes of bilateral blindness and visual impairment in an urban institutionalized population aged 65 years and older.
Methods. A total of 392 nursing home residents completed a standardized eye examination, including measurement of visual acuity (VA), intraocular pressure, lens opacity grading, indirect ophthalmoscopy, and photography of the macular area. The major causes of vision loss identified for all participants were blindness and visual impairment.
Results. The average subject age was 82 years (65¿97); women outnumbered men 263 to 129. The prevalence of bilateral blindness (VA ¿1.0 logarithm of the minimum angle of resolution [logMAR]) was 14.9% (43/288); the prevalence of visual impairment (VA ¿0.5 and 1.0 logMAR) was 31.9% (92/288). Blindness and visual impairment increased significantly with age (p<0.05), odds ratio (OR) 1.047 and 1.088, respectively. Cataract was the most common cause of bilateral blindness and visual impairment (27.9% and 44.6%, respectively) followed by pathologic myopia (23.3%) and age-related macular degeneration (AMD) (20.9%) for blindness, and by AMD (27.2%) and pathologic myopia (12%) for visual impairment. Fifty percent of subjects with visual loss had the potential for improved vision with medical or surgical intervention.
Conclusions. Although the prevalences were high, these data are important since it is difficult for epidemiologic studies to include aged, institutionalized individuals, although their numbers are increasing. Recognition of the predominant causes of visual loss dependent on age is fundamental for early diagnosis and treatment of ocular diseases. Many cases of low vision can be treated with appropriate ophthalmologic care.
Autores:
Blaizot, X.; Mansilla, F.; Insausti, A. M.; et al.
Revista:
CEREBRAL CORTEX
ISSN:
1047-3211
Año:
2010
Vol.:
20
N°:
9
Págs.:
2198 - 2212
The temporal pole (TP) is the rostralmost portion of the human temporal lobe. Characteristically, it is only present in human and nonhuman primates. TP has been implicated in different cognitive functions such as emotion, attention, behavior, and memory, based on functional studies performed in healthy controls and patients with neurodegenerative diseases through its anatomical connections (amygdala, pulvinar, orbitofrontal cortex). TP was originally described as a single uniform area by Brodmann area 38, and von Economo (area TG of von Economo and Koskinas), and little information on its cytoarchitectonics is known in humans. We hypothesize that 1) TP is not a homogenous area and we aim first at fixating the precise extent and limits of temporopolar cortex (TPC) with adjacent fields and 2) its structure can be correlated with structural magnetic resonance images. We describe here the macroscopic characteristics and cytoarchitecture as two subfields, a medial and a lateral area, that constitute TPC also noticeable in 2D and 3D reconstructions. Our findings suggest that the human TP is a heterogeneous region formed exclusively by TPC for about 7 mm of the temporal tip, and that becomes progressively restricted to the medial and ventral sides of the TP. This cortical area presents topographical and structural features in common with nonhuman primates, which suggests an evolutionary development in human species.
Nacionales y Regionales
Título:
Miopía vs Miopía patológica ¿dos procesos diferentes? Del exoma al estilo de vida. MYoriGENE Study
Código de expediente:
PI20/00251
Investigador principal:
Sergio Recalde Maestre
Financiador:
INSTITUTO DE SALUD CARLOS III
Convocatoria:
2020 AES Proyectos de investigación
Fecha de inicio:
01/01/2021
Fecha fin:
31/12/2023
Importe concedido:
92.565,00€
Otros fondos:
Fondos FEDER
Título:
Influencia de factores clínicos y genéticos en la evolución funcional y anatómica a largo plazo en una cohorte de pacientes con DMAE húmeda tratados según práctica clínica habitual
Código de expediente:
PI15/01374
Investigador principal:
Alfredo García Layana
Financiador:
INSTITUTO DE SALUD CARLOS III
Convocatoria:
2015 AES PROYECTOS DE INVESTIGACIÓN
Fecha de inicio:
01/01/2016
Fecha fin:
30/11/2020
Importe concedido:
92.565,00€
Otros fondos:
Fondos FEDER